explore -WSS

explore

author：fashion 2025-09-08 08:49:57 - browse：1

Japanese drugmaker Eisai said Tuesday that Ivan Cheung, chairman of its U.S. operations and global head of its Alzheimer’s disease unit, will retire at the end of the month. The surprise announcement comes just days after Eisai won final approval in the U.S. for its Alzheimer’s drug Leqembi.

Cheung will be replaced in his capacity as head of the Alzheimer’s unit by his brother-in-law Keisuke Naito, 34, who is currently chief ecosystem officer and chief strategy officer. He is also the son of Eisai CEO Haruo Naito.

Tatsuyuki Yasuno, current chief financial officer, will replace Cheung as head of Eisai’s U.S. unit.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Trump demands the U.S. pay no more for drugs than other countries … again
Next article： Flagship Pioneering launches a new biotech in two countries

WSS

Global cancer cases to surge 77% by 2050, WHO report says

Top private equity targets in 2023: cardiology, clinical trials, lasers

Novo Holdings to buy drug manufacturer Catalent in $16.5B deal

Medicare Advantage plans can’t deny care with AI, CMS warns

Disappointing trial forces Pfizer to pivot on obesity medicine plans

FDA investigates CAR

hotspot

explore

hotspot

Moonlake's readout produced a cash windfall. Risks remain

With clinical trial data readouts, here's how to spot spin

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

The Biogen Aduhelm mess could happen again

Guidelines to prevent youth baseball injuries need more muscle

Is mRNA technology the right fit for flu shots? Experts aren’t so sure

United colonoscopy coverage change 'may cost lives,' doctors say

Will the market for weight loss drugs really reach $100 billion?

23andMe had bad news about my health. I wish a person had delivered it

BIO selects John Crowley as new CEO

hotspot

UnitedHealth’s Optum accused of antitrust violations in California

As biotech industry slumps, bioscience job market is upside down

Mayo Clinic plans $5B tech

FDA investigates CAR

Is mRNA technology the right fit for flu shots? Experts aren’t so sure

UnitedHealth has 90,000 doctors — 10% of all physicians in U.S.

focus

explore

focus

focus